Application of astragaloside in preparation of product for improving heart FTO expression level

By increasing cardiac FTO expression and activating the FTO/AMPK signaling pathway, astragaloside A improves cardiotoxicity caused by antitumor drugs, especially heart failure, solving the problem of unclear molecular mechanisms in existing technologies and achieving improvement in myocardial energy metabolism.

CN119033799APending Publication Date: 2024-11-29DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE

Patent Information

Application Number
CN202411040709.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively address the cardiotoxicity, particularly heart failure, caused by antitumor drugs such as doxorubicin, and the molecular mechanisms involved remain unclear.

Method used

By using astragaloside A to increase the expression level of cardiac FTO, the FTO/AMPK signaling pathway is activated, and the expression of AMPK pathway-related genes such as GLUT4, PFKFB3, and CPT1A is enhanced, thereby improving myocardial energy metabolism.

Benefits of technology

Astragaloside A improves doxorubicin-induced cardiac dysfunction by regulating the FTO/AMPK pathway, thus expanding its application in the treatment of cardiotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033799A_ABST
    Figure CN119033799A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to application of astragaloside in preparation of a product for improving the heart FTO expression level. Research finds that astragaloside can improve expression of FTO in myocardial tissue of a Dox-induced HF mouse and improve protein and mRNA levels of AMPK and molecules such as downstream key enzymes GLUT4, PFKFB3 and CPT1A, which indicates that astragaloside can improve Dox-induced HF by regulating an FTO / AMPK signal channel and downstream molecules thereof. The research proves that the astragaloside can improve the CHF induced by adriamycin by activating the FTO / AMPK pathway, and the application range of the astragaloside is expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to an application of astragaloside IV in the preparation of a product for improving the expression level of cardiac FTO. Background Art

[0002] The high morbidity and mortality of cancer patients due to cardiotoxicity caused by anticancer drugs cannot be ignored. The most common chemotherapy drugs that induce cardiotoxicity in clinical practice are anthracyclines, with doxorubicin (Dox) as the main representative drug. The effectiveness of their treatment is limited by cumulative cardiotoxicity. Prevention and treatment of cardiotoxicity caused by anticancer drugs is a challenge faced by oncologists and cardiologists.

[0003] The fat mass and obesity associated gene (FTO) has been shown to be involved in the proliferation, apoptosis, migration, invasion and other processes of tumor cells, playing an important role in promoting tumors; interestingly, FTO also plays an important role in cardiac homeostasis and failure, but in contrast to its role in tumors, the expression of FTO in the mouse heart is significantly decreased during heart failure (HF), and the level of N6-methyladenosine (m6A) is significantly increased. Overexpression of FTO can alleviate cardiac dysfunction and improve myocardial remodeling. However, it is not completely clear which genes are affected by FTO-mediated m6A methylation and which pathophysiological processes lead to cardiac damage.

[0004] In previous studies, our team has demonstrated the efficacy of Xijiaqi prescription in various models of heart failure induced in mice, and it also has a certain preventive effect on Dox-induced cardiotoxicity.

[0005] However, its main active ingredients and specific molecular mechanisms need further study. Summary of the invention

[0006] Based on this, the present invention provides the use of astragaloside IV in the preparation of a product for improving the expression level of cardiac FTO.

[0007] In one embodiment, increasing the expression level of cardiac FTO includes increasing the mRNA level of FTO and increasing the protein level of FTO.

[0008] The present invention also provides the use of astragaloside IV in preparing a product for improving the expression level of cardiac AMPK pathway-related genes, wherein the AMPK pathway-related genes are one or more of AMPK, GLUT4, CPT1A and PFKFB3.

[0009] In one embodiment, the astragaloside IV increases the expression level of the AMPK pathway related genes by increasing the expression level of cardiac FTO.

[0010] In one embodiment, increasing the expression level of cardiac AMPK pathway-related genes includes increasing the mRNA level of the AMPK pathway-related genes and increasing the protein level of the AMPK pathway-related genes.

[0011] In one embodiment, the product is a pharmaceutical preparation.

[0012] In one embodiment, the pharmaceutical preparation comprises a pharmaceutically acceptable excipient.

[0013] In one embodiment, the dosage form of the pharmaceutical preparation is tablets, capsules, granules, oral solution or injection.

[0014] The beneficial effects of the present invention are:

[0015] This paper explores the molecular mechanism of astragaloside IV, the main active ingredient in Xijiaqi prescription, in treating HF. It is found that astragaloside IV can increase the expression of FTO in the myocardial tissue of Dox-induced HF mice, and at the same time increase the protein and mRNA levels of AMPK and its downstream key enzymes GLUT4, PFKFB3, CPT1A and other molecules, which indicates that astragaloside IV can improve Dox-induced HF by regulating the FTO / AMPK signaling pathway and its downstream molecules. This study proves that astragaloside IV can improve doxorubicin-induced CHF by regulating the FTO / AMPK pathway, expanding the scope of application of astragaloside IV. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 The immunohistochemical results of AS-IV enhancing the expression of FTO in myocardial tissue of HF mice in Example 1;

[0018] Figure 2 The immunohistochemical results of AS-IV in Example 1 showed that it increased the expression of AMPK in the myocardial tissue of HF mice;

[0019] Figure 3The experimental results of AS-IV in Example 1 for improving the expression of proteins related to the FTO / AMPK signaling pathway in the myocardial tissue of HF mice; wherein A is a representative Western blot diagram of proteins in the myocardial tissue of each group of mice; B is the relative expression of FTO protein in the myocardial tissue of each group of mice; C is the relative expression of AMPK protein in the myocardial tissue of each group of mice; D is the relative expression of GLUT4 protein in the myocardial tissue of each group of mice; E is the relative expression of PFKFB3 protein in the myocardial tissue of each group of mice; F is the relative expression of CPT1A protein in the myocardial tissue of each group of mice;

[0020] Figure 4 These are the experimental results of AS-IV improving the expression of mRNA related to the FTO / AMPK signaling pathway in the myocardial tissue of HF mice in Example 1; wherein A is the relative expression level of FTO mRNA in the myocardial tissue of each group of mice; B is the relative expression level of AMPK mRNA in the myocardial tissue of each group of mice; C is the relative expression level of GLUT4 mRNA in the myocardial tissue of each group of mice; D is the relative expression level of PFKFB3 mRNA in the myocardial tissue of each group of mice; E is the relative expression level of CPT1A mRNA in the myocardial tissue of each group of mice. DETAILED DESCRIPTION

[0021] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0022] Therefore, it is intended that the present invention covers such modifications and variations that fall within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. Those of ordinary skill in the art will appreciate that this discussion is only a description of exemplary embodiments and is not intended to limit the broader aspects of the present invention.

[0023] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any form. For those skilled in the art, any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention should all be equivalent replacement methods and are included in the protection scope of the present invention.

[0024] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0025] Xijiaqi Fang has a variety of effective substance components. The present invention first analyzed the main active ingredients that exert their efficacy by mass spectrometry, and the molecular docking results are shown in the table below. The docking results show that the docking binding energy of FTO with chrysanthemol is -6.6kcal / mol, the docking binding energy with astragalus polysaccharide is -6.6kcal / mol; the docking binding energy with schizonepeta aglycone is -7.5kcal / mol; the docking binding energy with astragaloside IV is -7.6kcal / mol. It is generally believed that a docking energy value less than -4.25kcal / mol indicates a certain binding activity between the two, less than -5.0kcal / mol indicates a good binding activity, and less than -7.0kcal / mol indicates a strong binding activity.

[0026] Serial number Effector Target (PDB number) <![CDATA[Binding energy / kcal·mol -1 > 1 Nonyl alcohol FTO(7E8Z) -6.6 2 Astragalus polysaccharide FTO(7E8Z) -6.6 3 Periploca glycoside FTO(7E8Z) -7.5 4 Astragaloside IV FTO(7E8Z) -7.6

[0027] The present invention further explores whether AS-IV can regulate energy metabolism and alleviate Dox-induced HF through the following examples.

[0028] Example 1

[0029] 1 Experimental Materials

[0030] 1.1 Experimental animals

[0031] A total of 90 SPF-grade C57BL / 6J male mice, 6 weeks old, weighing 20-25 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (Experimental Animal License No.: SCXK(Beijing)2020-0013) and housed in separate cages in the SPF-grade laboratory of the Experimental Animal Center of Beijing University of Chinese Medicine. The animal experiments were approved by the Experimental Animal Ethics Committee of Beijing University of Chinese Medicine, with the ethics review approval number: BUCM-2023041707-2109.

[0032] 1.2 Pharmacy and Reagents

[0033] The general reagents are shown in the following table, and other required reagents are also conventional commercially available products.

[0034]

[0035]

[0036]

[0037] 2 Experimental methods

[0038] 2.1 Solution preparation

[0039] 2.1.1 Preparation of doxorubicin solution

[0040] 25 mg of Dox was dissolved in 50 mL of 0.9% saline for injection to prepare a 0.5 mg / mL Dox solution.

[0041] 2.1.2 Preparation of Astragaloside IV Solution

[0042] First, prepare 0.5% sodium carboxymethyl cellulose solution, dissolve 0.5g sodium carboxymethyl cellulose in 100mL deionized water and set aside; then dissolve AS-IV in 0.5% sodium carboxymethyl cellulose solution to prepare AS-IV suspension, with final concentrations of 2mg / mL, 4mg / mL and 8mg / mL respectively, and use it by gavage.

[0043] 2.1.3 Preparation of trimetazidine solution

[0044] 30 mg of trimetazidine (TMZ) was dissolved in 20 mL of deionized water to prepare a trimetazidine solution with a concentration of 1.5 mg / kg, which was administered intragastrically.

[0045] 2.2 Animal modeling

[0046] C57BL / 6J male mice were injected intraperitoneally with 5 mg / kg Dox once a week for 4 consecutive weeks, with a cumulative dose of 20 mg / kg. The success of the model was judged by echocardiography, with LVEF ≤ 50% as the standard for successful modeling.

[0047] 2.3 Animal grouping and drug administration

[0048] The mice were randomly divided into blank control group (Control), model group (Dox), low-dose astragaloside IV group (Dox+AS-IV-L), medium-dose astragaloside IV group (Dox+AS-IV-M), high-dose astragaloside IV group (Dox+AS-IV-H) and trimetazidine group (Dox+TMZ) using a random number table method, and samples were collected 4 weeks after intragastric administration.

[0049] (1) Control group: deionized water was gavaged once a day for 4 weeks.

[0050] (2) Dox group: deionized water was administered intragastrically once a day for 4 weeks.

[0051] (3) Dox+AS-IV-L group: astragaloside IV (20 mg / kg / d) was administered orally for 4 consecutive weeks.

[0052] (4) Dox+AS-IV-M group: astragaloside IV (40 mg / kg / d) was administered orally for 4 consecutive weeks.

[0053] (5) Dox+AS-IV-H group: astragaloside IV (80 mg / kg / d) was administered orally for 4 consecutive weeks.

[0054] (6) Dox+TMZ group: trimetazidine (15 mg / kg / d) was administered intragastrically for 4 consecutive weeks.

[0055] 2.4 Mouse sampling

[0056] After intraperitoneal injection of sodium pentobarbital to anesthetize mice, venous blood was collected by eyeball extraction and placed in a 1.5 mL EP tube. The chest cavity was then quickly opened, and the fresh heart was cut. Part of the heart was fixed with a 4% paraformaldehyde solution, and part of the heart was placed in a cryotube and quickly frozen in liquid nitrogen, and then stored in a -80°C refrigerator. The blood was centrifuged at 3000 r / min for 20 minutes, and the upper serum was collected and stored in a -80°C refrigerator for testing.

[0057] 2.5 Immunohistochemistry

[0058] The sections are routinely dewaxed to water; antigen retrieval, to restore the antibody reactivity of the antigen; blocking, adding nonspecific antiserum to block nonspecific binding sites in the tissue sections; primary antibody incubation: coating the specific primary antibody on the tissue sections for incubation; secondary antibody incubation: coating the labeled secondary antibody on the tissue sections for incubation to form an antigen-antibody-antibody complex; color development observation, and then observing the distribution and expression of the target antigen in the tissue under a microscope.

[0059] 2.6WB

[0060] (1) Total protein extraction: prepare lysis buffer (RIPA: protease phosphoinhibitor: PMSF = 100:1:1) according to the ratio, add to tissues or cells, homogenize (tissue) or ultrasonically disrupt (cells) on ice, and then stand on ice for 20 min to allow for sufficient lysis; precool the centrifuge at 12,000 rpm, 4°C, for 15 min, and collect the supernatant.

[0061] (2) Prepare BCA working solution: Total amount of BCA working solution = (number of standard samples + number of unknown samples) * number of replicate wells * volume of BCA working solution for each sample. Solution A: Solution B = 50:1, mix thoroughly. Add 200 μL of working solution to each well.

[0062] (3) Quantitative detection: Add 25 μL of the diluted BSA standard and the protein sample to be tested to the wells of a 96-well microplate. The concentration of the sample should be diluted 5 or 10 times in advance. Add 200 μL of BCA working solution to each well, mix thoroughly, cover the 96-well plate, incubate at 37°C for 30 minutes, cool to room temperature, and complete the detection within 3 to 5 minutes. Use an ELISA reader to measure the absorbance of each sample and BSA standard at 562 nm and keep a record. Calculate the protein concentration in the sample by drawing a standard curve. Calculate the volume of loading buffer according to the concentration.

[0063] (4) Protein denaturation: Cook at 95-100℃ for 5-10 min. Immediately cool on ice for 5 min and store in a -80℃ refrigerator.

[0064] (5) Electrophoresis: Use 10% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), add the marker and protein sample to the sample tank, keep the voltage at 90V, and run the electrophoresis for 30 min. When the band moves from the upper gel into the lower gel and becomes a thin line, set the voltage to 120V. Stop the electrophoresis when the bromophenol blue in the sample moves to the bottom.

[0065] (6) Electrotransfer: Open the transfer clip and assemble the transfer clip from the negative electrode to the positive electrode in the order of sponge, filter paper, gel, nitrocellulose filter membrane (NC), filter paper, and sponge. Fix the transfer clip on the electrotransfer device and put it into the electrotransfer tank, and add the transfer solution. Connect the electrotransfer tank electrodes, keep the constant current at 400 mA, and electrotransfer for 40 minutes. Transfer the protein to the NC membrane.

[0066] (7) Blocking and antibody incubation: Place the membrane in 5% skim milk and block on a shaker for 120 minutes. After blocking, cut the membrane according to the position of the marker and the molecular weight of the target protein; place the membrane with the target protein in the corresponding primary antibody dilution and incubate it in a refrigerator at 4°C overnight. Wash with TBST solution 4 times, 10 minutes each time, remove the residual primary antibody dilution, place in the corresponding secondary antibody dilution, and incubate at room temperature for 60 minutes. Wash with TBST solution 8 times, 5 minutes each time.

[0067] (8) Exposure: Add luminescent solution and develop in a gel imager. Finally, use Image J software to analyze the signal.

[0068] 2.7PCR

[0069] First, use the reverse transcription kit to configure the system according to the instructions to reverse transcribe RNA into cDNA; second, use SYBR qPCR mixture to configure the mixture according to the instructions. Finally, amplify on the PCR instrument. -ΔΔCT The mRNA level of the target gene was calculated by the method and normalized with the mRNA level of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene to determine the fold change of the relative expression of the target gene.

[0070] ΔΔCT method:

[0071] A = CT (target gene, sample to be tested) - CT (internal standard gene, sample to be tested)

[0072] B = CT (target gene, control sample) - CT (internal standard gene, control sample)

[0073] K = AB expression multiple = 2 -K

[0074] 2.8 Statistical methods

[0075] SPSS 25.0 software was used for statistical analysis. The measurement data were in accordance with normal distribution and homogeneity of variance, and the mean ± standard deviation was used. One-way ANOVA was used for comparison among multiple groups, and LSD method was used for pairwise comparison among groups; otherwise, Kruskal-Wails test was used. P<0.05 was considered statistically significant, P<0.01, and P<0.001 were considered statistically significant.

[0076] 3 Experimental results

[0077] 3.1 Immunohistochemistry suggests that AS-IV can increase the expression of FTO and AMPK in myocardial tissue of HF mice

[0078] In order to explore the mechanism of action of AS-IV, immunohistochemistry was performed on the myocardial tissues of mice in each group to detect the expression of FTO and AMPK. The results of immunohistochemistry showed that compared with the control group, the expression of FTO in the Dox group was reduced, and the expression of FTO in the myocardial tissues of mice in the low, medium, and high doses of astragaloside IV groups showed a significant increase (e.g. Figure 1 Similarly, it was observed that AMPK was widely expressed in myocardial tissue, but compared with the control group, the expression of AMPK was significantly reduced after Dox intervention, and the low, medium and high doses of astragaloside IV could increase the expression of AMPK to varying degrees (as shown in Figure 2 shown).

[0079] 3.2AS-IV can increase the expression of FTO / AMPK signaling pathway-related proteins in myocardial tissue of HF mice

[0080] Compared with the normal group, the protein expressions of FTO, AMPK, GLUT4, PFKFB3 and CPT1A in the myocardial tissue of the mice in the model group were significantly decreased; compared with the model group, the protein expressions of FTO and AMPK in the myocardial tissue of the AS-IV low, medium and high dose groups were significantly increased, and the protein expressions of their downstream molecules GLUT4, PFKFB3 and CPT1A were also significantly increased (e.g. Figure 3 Compared with the control group (Control), ** P<0.01, *** P<0.001; compared with the model group (Dox), # P<0.05, ## P<0.01, ### P<0.001. Low-dose astragaloside IV group; Dox+AS-IV-M, medium-dose astragaloside IV group; Dox+AS-IV-H, high-dose astragaloside IV group.

[0081] 3.3AS-IV can increase the expression of mRNA related to the FTO / AMPK signaling pathway in myocardial tissue of HF mice

[0082] The expression levels of related mRNA in the myocardial tissue of mice in each group were detected. The results showed that compared with the normal group, the expression of FTO, AMPK, GLUT4, PFKFB3, and CPT1A mRNA in the myocardial tissue of the model group mice was significantly reduced; compared with the model group, the mRNA levels of FTO and AMPK in the myocardial tissue of the low, medium, and high doses of astragaloside IV groups were significantly increased, and the expression of its downstream molecules GLUT4, PFKFB3, and CPT1A mRNA also increased significantly (e.g. Figure 4 Compared with the control group (Control), *** P<0.01, *** P<0.001; compared with the model group (Dox), # P<0.05, ## P<0.01, ### P<0.001. Low-dose astragaloside IV group; Dox+AS-IV-M, medium-dose astragaloside IV group; Dox+AS-IV-H, high-dose astragaloside IV group.

[0083] 4 Summary

[0084] The results of this study confirmed that AS-IV can promote glucose uptake and fatty acid oxidation by activating the FTO / AMPK signaling pathway, thereby increasing ATP content in the mouse heart and improving HF.

[0085] Multiple studies have reported that Dox can cause an imbalance in myocardial energy metabolism. Therefore, regulating energy metabolism is an attractive approach to treat Dox-induced HF. In eukaryotic cells, AMPK plays an important role in regulating cellular energy balance. AMPK is a key regulator of energy metabolism, which can improve the imbalance of energy supply and demand in failing hearts by activating multiple enzymes, controlling multiple metabolic pathways, and increasing substrate supply to cardiomyocytes. In addition to its role in maintaining intracellular energy balance, AMPK also regulates systemic energy metabolism. AMPK can directly phosphorylate key factors involved in multiple pathways to restore energy balance. AMPK can mediate the translocation of GLUT4 from the cytoplasm to the cell membrane, thereby increasing glucose uptake and utilization, indicating that the activation of AMPK / GLUT4 is a cardioprotective and adaptive response of the heart. This study showed that Dox induced a significant decrease in AMPK activity, a significant decrease in the expression of GLUT4 and PFKFB3 in the heart, thereby impairing glucose aerobic oxidation and glycolysis, resulting in a decrease in glucose utilization and glucose accumulation in the myocardium. AS-IV can enhance AMPK activity, promote glucose metabolism, and increase ATP content after Dox treatment. On the other hand, AMPK activation is closely related to fatty acid metabolism. AMPK activation can promote the transport of fatty acids to mitochondria through CPT1A for β-oxidation. In this study, after Dox treatment, the expression of CPT1A and the β-oxidation level of fatty acids in the myocardium were significantly reduced, resulting in the accumulation of free fatty acids and the decrease of ATP levels in the myocardium. However, AS-IV could significantly reverse the above changes caused by Dox.

[0086] In summary, this study demonstrated that AS-IV could improve doxorubicin-induced HF by increasing ATP content through activating the FTO / AMPK signaling pathway.

[0087] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0088] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Application of astragaloside IV in the preparation of products for increasing the expression level of cardiac FTO.

2. The use according to claim 1, characterized in that: The increasing the expression level of cardiac FTO includes increasing the mRNA level of FTO and increasing the protein level of FTO.

3. Use of astragaloside IV in the preparation of a product for increasing the expression level of genes related to the cardiac AMPK pathway, characterized in that: The AMPK pathway related genes are one or more of AMPK, GLUT4, CPT1A and PFKFB3.

4. The use according to claim 3, characterized in that: The astragaloside IV increases the expression level of the AMPK pathway-related genes by increasing the expression level of cardiac FTO.

5. The use according to claim 3, characterized in that: The increasing the expression level of the cardiac AMPK pathway-related gene includes increasing the mRNA level of the AMPK pathway-related gene and increasing the protein level of the AMPK pathway-related gene.

6. The use according to any one of claims 1 to 5, characterized in that: The product is a pharmaceutical preparation.

7. The use according to claim 6, characterized in that: The pharmaceutical preparation comprises pharmaceutically acceptable excipients.

8. The use according to claim 6, characterized in that: The dosage form of the pharmaceutical preparation is tablet, capsule, granule, oral solution or injection.

Citation Information

Patent Citations

  • Protection effects of Astragaloside on heart

    CN104147030A

Cited By

  • Traditional Chinese medicine composition and application thereof

    CN117752671A